GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » EBITDA Margin %

Abaxis (Abaxis) EBITDA Margin % : 21.01% (As of Mar. 2018)


View and export this data going back to 1992. Start your Free Trial

What is Abaxis EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Abaxis's EBITDA for the three months ended in Mar. 2018 was $14.3 Mil. Abaxis's Revenue for the three months ended in Mar. 2018 was $67.9 Mil. Therefore, Abaxis's EBITDA margin for the quarter that ended in Mar. 2018 was 21.01%.


Abaxis EBITDA Margin % Historical Data

The historical data trend for Abaxis's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis EBITDA Margin % Chart

Abaxis Annual Data
Trend Mar09 Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.54 21.12 24.24 22.81 19.07

Abaxis Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.63 17.88 19.35 17.75 21.01

Competitive Comparison of Abaxis's EBITDA Margin %

For the Diagnostics & Research subindustry, Abaxis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abaxis's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Abaxis's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Abaxis's EBITDA Margin % falls into.



Abaxis EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Abaxis's EBITDA Margin % for the fiscal year that ended in Mar. 2018 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2018 )/Revenue (A: Mar. 2018 )
=46.661/244.7
=19.07 %

Abaxis's EBITDA Margin % for the quarter that ended in Mar. 2018 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2018 )/Revenue (Q: Mar. 2018 )
=14.268/67.918
=21.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abaxis  (NAS:ABAX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Abaxis EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Abaxis's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abaxis (Abaxis) Business Description

Traded in Other Exchanges
N/A
Address
Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.
Executives
Richard Bastiani director C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr officer: CFO and VP of Finance C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson director, officer: CEO & Board Chairman C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020